Reference

AMET works diligently to keep the following information updated with the most current medical aesthetic news.  This information has been supplied by numerous sources. AMET is not affiliated with any such sources, and the information provided does not reflect the views of AMET.  The function of this page is to simply provide information, and AMET does not accept responsibility or liability for any views/claims/rumors/errors that appears herein.  

8/9/2015
Patients give facial filler high ratings
Results of a recent study show that patients treated with Juvderm Voluma XC are highly satisfied with their results.
Patients give facial filler high ratings

Results of a recent study show that patients treated with Juvderm Voluma XC are highly satisfied with their results.

Allergans Juvderm Voluma XC is a hyaluronic acid filler used for correcting age-related midface volume deficit (MVD). The study, headed by Julius Few, M.D., clinical professor of surgery in the Division of Plastic Surgery at the University of Chicago Pritzker School of Medicine, sought to get patients input on the fillers effectiveness.

A total of 235 patients with moderate to severe age-related MVD participated in the study. During quarterly follow-up visits over two years following treatment with Juvderm Voluma XC, the patients rated treatment outcomes on the Global Aesthetic Improvement Scale (GAIS), overall satisfaction with facial appearance, satisfaction with midfacial regions, achievement of treatment goal, look and feel of the midface (LAFM) and self-perception of age (SPA). Patients recorded treatment-site responses in 30-day diaries.

The mean injection volume (both sides of the face) for initial and touch-up treatments combined was 6.68 mL. The mean injection volume for initial treatment was 5.09 mL and 1.93 mL for touch-up treatment. Mean injection volumes for initial and touch-up treatments combined for the zygomaticomalar region, anteromedial cheek and submalar region were 2.39 mL, 2.12 mL and 2.42 mL, respectively. Both subcutaneous and supraperiosteal injection planes were used for 67.3%, 54.9% and 24.5% of injections in the zygomaticomalar region, anteromedial cheek and submalar region, respectively. The remainder of injections used only one of the injection planes.
To read the entire article, click on the link.

http://cosmeticsurgerytimes.modernmedicine.com/cos...

back to reference main